WallStreetZenWallStreetZen

NASDAQ: XTLB
Xtl Biopharmaceuticals Ltd Stock

$2.61+0.03 (+1.16%)
Updated May 24, 2024
XTLB Price
$2.61
Fair Value Price
$0.26
Market Cap
$14.22M
52 Week Low
$0.75
52 Week High
$4.99
P/E
-8.7x
P/B
6.41x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$1.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$707k
Beta
0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

XTLB Overview

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XTLB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

XTLB ($2.61) is overvalued by 915.14% relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
XTLB ($2.61) is not significantly undervalued (915.14%) relative to our estimate of its Fair Value price of $0.26 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
XTLB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more XTLB due diligence checks available for Premium users.

Be the first to know about important XTLB news, forecast changes, insider trades & much more!

XTLB News

Valuation

XTLB fair value

Fair Value of XTLB stock based on Discounted Cash Flow (DCF)
Price
$2.61
Fair Value
$0.26
Overvalued by
915.14%
XTLB ($2.61) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
XTLB ($2.61) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
XTLB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

XTLB price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-8.7x
Industry
15.58x
Market
32.03x

XTLB price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
6.41x
Industry
6.08x
XTLB is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

XTLB's financial health

Profit margin

Revenue
$0.0
Net Income
-$1.8M
Profit Margin
0%
XTLB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$2.4M
Liabilities
$206.0k
Debt to equity
0.09
XTLB's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XTLB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$707.0k
Investing
$41.0k
Financing
$0.0
XTLB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

XTLB vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
XTLB$14.22M+1.16%-8.70x6.41x
IMNN$14.20M+4.14%-0.75x1.67x
KPRX$14.34M+2.44%-0.49x0.41x
EDSA$14.09M-1.90%-1.85x3.26x
PIRS$13.84M-0.10%-0.88x0.63x

Xtl Biopharmaceuticals Stock FAQ

What is Xtl Biopharmaceuticals's quote symbol?

(NASDAQ: XTLB) Xtl Biopharmaceuticals trades on the NASDAQ under the ticker symbol XTLB. Xtl Biopharmaceuticals stock quotes can also be displayed as NASDAQ: XTLB.

If you're new to stock investing, here's how to buy Xtl Biopharmaceuticals stock.

What is the 52 week high and low for Xtl Biopharmaceuticals (NASDAQ: XTLB)?

(NASDAQ: XTLB) Xtl Biopharmaceuticals's 52-week high was $4.99, and its 52-week low was $0.75. It is currently -47.7% from its 52-week high and 248% from its 52-week low.

How much is Xtl Biopharmaceuticals stock worth today?

(NASDAQ: XTLB) Xtl Biopharmaceuticals currently has 544,906,149 outstanding shares. With Xtl Biopharmaceuticals stock trading at $2.61 per share, the total value of Xtl Biopharmaceuticals stock (market capitalization) is $14.22M.

Xtl Biopharmaceuticals stock was originally listed at a price of $6.50 in Nov 18, 2008. If you had invested in Xtl Biopharmaceuticals stock at $6.50, your return over the last 15 years would have been -59.85%, for an annualized return of -5.9% (not including any dividends or dividend reinvestments).

How much is Xtl Biopharmaceuticals's stock price per share?

(NASDAQ: XTLB) Xtl Biopharmaceuticals stock price per share is $2.61 today (as of May 24, 2024).

What is Xtl Biopharmaceuticals's Market Cap?

(NASDAQ: XTLB) Xtl Biopharmaceuticals's market cap is $14.22M, as of May 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Xtl Biopharmaceuticals's market cap is calculated by multiplying XTLB's current stock price of $2.61 by XTLB's total outstanding shares of 544,906,149.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.